Although DAT appears to be a reliable marker of progression in relation to dopaminergic pathology, synaptic imaging with PET provides an important advantage by allowing tracking of the impact of PD pathology on non-dopaminergic systems, as well as in cortical areas. The gene discussed is SLC6A3; the disease is Parkinson disease.